-
-
-
-
-
-
-
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
-
-
-
-
-
-
-
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
-
-
-
-
-
-
-
FDA approves BeOne's (ONC) BRUKINSA tablet
-
-
-
-
-
-
-
BeiGene Ltd. (ONC) PT Raised to $259 at Bernstein After 'Asset and Market Model Updates'
-
-
-
-
-
-
-
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
-
-
-
-
-
-
-
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
-
-
-
-
-
-
-
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
1,219,403 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

